Welcome to our dedicated page for Delcath Sys news (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Sys stock.
The Delcath Systems Inc (DCTH) news page on Stock Titan aggregates company announcements, clinical updates, and financial disclosures for this interventional oncology business focused on primary and metastatic liver cancers. Delcath’s communications frequently highlight developments related to its proprietary hepatic delivery technologies, HEPZATO KIT and the CHEMOSAT Hepatic Delivery System for Melphalan, which are used in percutaneous hepatic perfusion (PHP) procedures.
Investors and observers can use this news feed to follow earnings reports and financial updates, including quarterly and preliminary revenue results, product revenue from HEPZATO KIT in the United States and CHEMOSAT in Europe, gross margin commentary, and discussions of non-GAAP measures such as adjusted EBITDA. The company also issues releases on capital allocation and corporate actions, such as authorization of share repurchase programs and equity inducement grants under stock incentive plans.
A significant portion of Delcath’s news flow centers on clinical and scientific developments. Recent announcements describe subgroup analyses from the Phase 3 FOCUS study of Melphalan/Hepatic Delivery System in unresectable metastatic uveal melanoma, the Phase 2 CHOPIN trial evaluating CHEMOSAT with ipilimumab and nivolumab, real-world evidence from retrospective analyses of metastatic uveal melanoma patients, and a 10-year single-center experience with CHEMOSAT in liver-dominant disease. The company also highlights expert narrative reviews discussing PHP with melphalan using HEPZATO KIT, including patient selection, technique, and outcomes.
Additional updates include participation in investor conferences and scheduling of earnings calls, providing context for how Delcath communicates with the capital markets. For users tracking DCTH, this page offers a centralized view of regulatory, clinical, and financial news that shapes the company’s progress in liver-directed oncology therapies. Bookmark this feed to monitor new data releases, product-related publications, and ongoing disclosures from Delcath Systems Inc.
Delcath Systems, focused on liver-directed treatments, announced its participation in two investor conferences. The first is the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 4:30 PM EDT, featuring a live webcast. The second event is the Oppenheimer Fall Healthcare Life Science & Med Tech Summit on September 23, 2020. Virtual one-on-one meetings with management can be scheduled. Delcath's investigational product, Melphalan Hydrochloride for Injection, targets liver cancer treatment and has not yet received FDA approval.
Delcath Systems, a company specializing in interventional oncology for liver cancers, will present at the LD Micro 500 Virtual Conference on September 1, 2020, at 3:00 PM ET. A live webcast of this presentation will be publicly accessible and archived for 90 days. Delcath is known for its innovative treatment Melphalan Hydrochloride, designed for high-dose localized chemotherapy, and is conducting Phase 3 clinical trials for various liver cancers, including intrahepatic cholangiocarcinoma. The company’s system is marketed in Europe under the name Delcath CHEMOSAT.
Delcath Systems (NASDAQ: DCTH) reported its Q2 2020 financial results, highlighting a net loss of $4.3 million, improving from a $6.0 million loss the previous year. Product revenue rose to $262,000, up from $221,000. The company completed a $22 million public offering aimed at funding a Phase 3 trial for Melphalan/HDS in metastatic ocular melanoma (mOM). Delcath also emphasized plans for NDA submission by mid-2021 and further clinical studies in liver-dominant cancers, with cash resources sufficient until mid-2021.
Delcath Systems (NASDAQ: DCTH) announced that John Purpura, interim CEO, will present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 9 a.m. ET. A webcast of the presentation will be available for viewing. The company, renowned for its liver-directed treatments for cancers, is also engaging in one-on-one investor meetings. Delcath’s investigational product, Melphalan Hydrochloride for Injection, aims to deliver high-dose chemotherapy to the liver while minimizing systemic exposure. The system has not yet received FDA approval but is marketed in Europe as CHEMOSAT.